Innovent Biologics Reports Strong GLP-1 Revenue and Sets Ambitious 2030 Targets

Innovent Biologics released earnings data highlighting robust revenue from GLP-1 drugs and announced ambitious revenue projections for 2030, prompting a 15% upward revision in fair value estimates.

26 Aug, 06:40 — 26 Aug, 06:40

Post Share

Sources

Showing 1 of 1 sources

morningstar5d ago

Innovent Earnings: Provides Lofty Revenue Target for 2030; GLP-1 Revenue Robust; Fair Value Up 15% - Morningstar

Innovent Earnings: Provides Lofty Revenue Target for 2030; GLP-1 Revenue Robust; Fair Value Up 15% Morningstar

Read full article →

Innovent Biologics Reports Strong GLP-1 Revenue and Sets Ambitious 2030 Targets

Sources

Innovent Earnings: Provides Lofty Revenue Target for 2030; GLP-1 Revenue Robust; Fair Value Up 15% - Morningstar

Related Stories

Shein Shares Drop in Disappointing Hong Kong Stock Market Debut

Modi Hails India’s 7.8% GDP Growth While Promoting Swadeshi Campaign

Japanese Corporations Increase Capital Spending Amid Profit Surge

White House Details Controversial Oil Deal with Venezuelan Partner NABEP